Brief: Medivir Enters Exclusive Licensing Agreement With Biosil

Medivir AB

23/10/2025 07:32

Oct 23 (Reuters) - Medivir AB MEDIVIR.ST:

ENTERS EXCLUSIVE LICENSING AGREEMENT WITH BIOSIL FOR REMETINOSTAT

TO RECEIVE UP TO USD 60 MILLION PLUS ROYALTIES

Source text: ID:nMFN5Vd0Np

Further company coverage: MEDIVIR.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))